Skip Navigation



JAC Advance Access published online on July 28, 2004
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkh387
© 2004 by The British Society for Antimicrobial Chemotherapy
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
54/3/648    most recent
dkh387v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kruszewska, D.
Right arrow Articles by Ljungh, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kruszewska, D.
Right arrow Articles by Ljungh, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Received January 14, 2004
Revised June 15, 2004
Accepted June 20, 2004

Original article

Mersacidin eradicates methicillin-resistant Staphylococcus aureus (MRSA) in a mouse rhinitis model

Danuta Kruszewska 1*, Hans-Georg Sahl 2, Gabriele Bierbaum 2, Ulrike Pag 2, Sean O. Hynes 1, Åsa Ljungh 1

1 Department of Medical Microbiology, Dermatology and Infection, Lund University, Sölvegatan 23, SE-223 62 Lund, Sweden
2 Institute for Medical Microbiology and Immunology, University of Bonn, Sigmund-Freud-Str. 25, 53105 Bonn, Germany

* To whom correspondence should be addressed. E-mail: Danuta.Kruszewska{at}telia.com.


  Abstract

Objectives: Methicillin-resistant Staphylococcus aureus (MRSA) often colonize the anterior nares, and nasal carriage remains the main source of bacterial dissemination. The aim of this study was to assess the in vivo activity of the lantibiotic mersacidin against MRSA colonizing nasal epithelia.

Methods: The efficiency of mersacidin in the eradication of MRSA was tested employing mice pre-treated with hydrocortisone and inoculated intranasally either three or six times with a bacterial suspension.

Results: In mersacidin-treated animals, pre-colonized with MRSA, bacteria could not be detected in blood, lungs, liver, kidney, spleen or nasal scrapings and there were no lesions manifested after intraperitoneal drug application. Blood samples from infected mice obtained 2 h after mersacidin therapy revealed anti-MRSA activity in a serum bactericidal test. Moreover, elevated interleukin-1{beta} and tumour necrosis factor-{alpha} titres were noticed in the pre-infected but not in cured animals. In contrast, mersacidin did not induce differences in the cytokine profiles of treated uninfected control mice.

Conclusions: In the mouse rhinitis model, mersacidin was able to eradicate MRSA colonization. The site of action (epithelium versus blood) of mersacidin needs to be further explored.

Keywords: lantibiotics; mouse model; MRSA nasal carriage.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Appl. Environ. Microbiol.Home page
M. Begley, P. D. Cotter, C. Hill, and R. P. Ross
Identification of a Novel Two-Peptide Lantibiotic, Lichenicidin, following Rational Genome Mining for LanM Proteins
Appl. Envir. Microbiol., September 1, 2009; 75(17): 5451 - 5460.
[Abstract] [Full Text] [PDF]

Home page
 Appl. Environ. Microbiol.Home page
M. de Kwaadsteniet, K. ten Doeschate, and L. M. T. Dicks
Characterization of the Structural Gene Encoding Nisin F, a New Lantibiotic Produced by a Lactococcus lactis subsp. lactis Isolate from Freshwater Catfish (Clarias gariepinus)
Appl. Envir. Microbiol., January 15, 2008; 74(2): 547 - 549.
[Abstract] [Full Text] [PDF]

Home page
 Appl. Environ. Microbiol.Home page
G. Valsesia, G. Medaglia, M. Held, W. Minas, and S. Panke
Circumventing the Effect of Product Toxicity: Development of a Novel Two-Stage Production Process for the Lantibiotic Gallidermin
Appl. Envir. Microbiol., March 1, 2007; 73(5): 1635 - 1645.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Microbiol. Rev.Home page
H. Jenssen, P. Hamill, and R. E. W. Hancock
Peptide Antimicrobial Agents
Clin. Microbiol. Rev., July 1, 2006; 19(3): 491 - 511.
[Abstract] [Full Text] [PDF]

Home page
 Appl. Environ. Microbiol.Home page
P. D. Cotter, L. A. Draper, E. M. Lawton, O. McAuliffe, C. Hill, and R. P. Ross
Overproduction of wild-type and bioengineered derivatives of the lantibiotic lacticin 3147.
Appl. Envir. Microbiol., June 1, 2006; 72(6): 4492 - 4496.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
A. C. Schaffer, R. M. Solinga, J. Cocchiaro, M. Portoles, K. B. Kiser, A. Risley, S. M. Randall, V. Valtulina, P. Speziale, E. Walsh, et al.
Immunization with Staphylococcus aureus Clumping Factor B, a Major Determinant in Nasal Carriage, Reduces Nasal Colonization in a Murine Model
Infect. Immun., April 1, 2006; 74(4): 2145 - 2153.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.